Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Fallopian Tube Neoplasms

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Fallopian Tube Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Fallopian Tube Cancer

Antineoplastic Agents

All Drugs and Chemicals

Etoposide

Paclitaxel

Carboplatin

Docetaxel

Albumin-Bound Paclitaxel

Cisplatin

Etoposide phosphate

Taxane

Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin

IV paclitaxel plus carboplatin or docetaxel plus carboplatin

IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5

PEip (weekly) and TCiv

IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5

TCiv

Rongyu Zang, MD,PhD

The purpose of this study is to evaluate the role of an additional intraperitoneal chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.

This exploratory trial is to compare the efficacy of sequential chemotherapy, intraperitoneal chemotherapy followed by intravenous chemotherapy, versus intravenous chemotherapy alone in the first-line therapy for ovarian cancer.

First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer

A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)

Fudan University

Shanghai Jiao Tong University School of Medicine

Shanghai Zhongshan Hospital

Shanghai Gynecologic Oncology Group

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer	NCT01669226	Bulky Stage III... Fallopian Tube ... Primary Periton...	PEip (weekly) a... TCiv	18 Years - 75 Years	Shanghai Gynecologic Oncology Group
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer	NCT01669226	Bulky Stage III... Fallopian Tube ... Primary Periton...	PEip (weekly) a... TCiv	18 Years - 75 Years	Shanghai Gynecologic Oncology Group

Spots Global Cancer Trial Database for tciv

Every month we try and update this database with for tciv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for tciv

Every month we try and update this database with for tciv cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tciv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.